N4 increases investment in NeuroClin

Eurazeo fund in first growth equity deal; European IPOs slow.

18 January 2024•4 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.